关于三氧化二砷(As_2O_3)联合药物治疗肝癌的研究进展

On the Effect of Trioxide (As_2O_3) Combined with Drugs in the Treatment of Liver Cancer

实验与临床研究已证实,As2O3能有效治疗急性早幼粒细胞性白血病(APL)。在此基础上.As2O3抗肝癌作用的研究报告日益增多。研究表明As2O3的抗肝癌效力呈剂量-时间效应关系,但作用时间越长及药物浓度越大,As2O3的毒副作用越大。为实现As2O3低毒高效的抗肿瘤目的,联合用药引起关注。本文通过查阅94年至今国内外有关As2O3药物联合治疗肝癌的文献,对As2O3联合药物治疗肝癌予以综述。

Experimental and clinical studies have demonstrated that arsenic trioxide had effect on the treatment of acute pro-myelocytic leukemia （APL）. Based on this fact, more and more studies have been carried out to study its role in treatment of human hepatocellular carcinoma. And studies show that As2O3.s anti-human-hepatocellular-carcinoma effect is a dose-time effect relationship, but as the longer the duration and the higher drug concentration,As2O3.s poisonous side effect is bigger. So in order to achieve As2O3.S more efficient anti-cancer purposes with lower dose, combination is concerned. This article reviewed domestic and foreign literature from 1994 to now in treatment ofhepatocellular carcinoma with arsenic trioxide combined other medicine.